The PD-1/PD-L1 axis, targeted by immune check point inhibitor antibodies, is gaining attention as an immunotherapeutic approach in sepsis due to its successful application in the treatment of infectious diseases and regression of advanced-stage cancers (128, 129). Here, PDCD1 is linked to cancer.